NewAmsterdam Pharma
Developing transformative, clinically validated oral therapies for patients with metabolic diseases.
Market cap
$2.1b
Enterprise value
$1.3b
Share price
$18.11 NAMS
Company register number
05266586
Authorizing premium user...
Developing transformative, clinically validated oral therapies for patients with metabolic diseases.